We have added a new secure online ordering system to make it easier to order our products. We are able to accept both Visa or Mastercard. For large or PO orders please email us for a price quote and ordering details.
We have changed our mailing address. Our new address is 12 Mill St, Bendigo, VIC, 3550, Australia. All our other contact details remain the same.
We hope you had a great break over Christmas and we wish you all the best in 2006.
Nucleics has updated our web site. We hope you like the new look.
Nucleics has appointed Mr David Gemmola to the newly created position of General Manager. David has extensive experience in the management and growth of early stage high technology companies. He brings to Nucleics a focus on product development and management.
Nucleics announces a project to sequence the Streptococcus gordonii DL1 genome using the ASIN genome sequencing technology developed by Nucleics. Streptococcus gordonii is an oral pathogen that can cause severe heart valve damage. This project is being performed in collaboration with Professor N A Jacques from Institute of Dental Research in Sydney. Approximately 25% of the genome sequence was completed in a pilot project in December 2000.
The ASIN technology was sold to Takara Biomedicals in March 2000, however, Nucleics retains the right to use the technology internally for non-commercial projects.
Nucleics has been awarded a three year R&D START grant of $1,834,000 from AusIndustry to develop new automated DNA sequencing technologies. These integrated technologies improve the preparation of the DNA template, the selection of the required oligonucleotide primers, the sequencing reaction read length, and the DNA polymerase. The synergy obtained by integration of these components will provide the biomedical community with considerable time and money savings over current approaches.
For further information on the R&D START scheme please contact AusIndustry.
Nucleics announces the sale of its novel genome DNA sequencing technology (ASIN) to Takara Biomedicals, a division of Takara Shuzo. Under the terms of the agreement, Takara has purchased all IP associated with the ASIN sequencing technology. Takara Biomedical Group has applied for worldwide patents on this technology.